The central area near the surgical treatment of gliomas 64002) [keywords] bronchiolitis ammonia, bromine cable adjuvant therapy [CLC] R562.1 [Document code] B [Article ID] 1008-6633 (20O6) 04-0497-01 Bronchiolitis is a more common lower respiratory tract infection in winter and spring, commonly known as pneumonia. It is common in infants, with respiratory syncytial virus (RSV) being the most common pathogen. Symptoms include fever, shortness of breath, coughing, wheezing, etc., and clinically, severe cases can cause respiratory failure and heart failure leading to death. Therefore, it is necessary to timely control symptoms and prevent the progression of the disease, which is the purpose of clinical treatment. From September 2003 to September 2005, we added ambroxol treatment on the basis of conventional treatment, obtaining better clinical results, reported as follows.
1 Materials and Methods
1.1 General information: 108 patients with bronchiolitis diagnosis were in line with the diagnostic criteria of bronchiolitis... 58 males, 50 females; aged 3 to 18 months. Clinical manifestations included 42 cases of fever (38.9%), cough, 108 cases (100%) of shortness of breath, and wheezing in 57 cases (52.8%). All children had audible wheeze in the lungs, some accompanied by fine wet rales. The observation group consisted of 60 cases and the control group of 48 cases, randomly divided into two groups. There was no significant difference between the two groups in terms of age, gender, pre-treatment duration, symptoms, and signs (P>0.05), making them comparable.
1.2 Treatment: Both groups of children received conventional treatment (anti-infection, hormones, symptomatic treatment, etc.). On the basis of conventional therapy, the observation group was given ambroxol (Mucosolvan, Boehringer Ingelheim International, Inc. products). For children aged 3 to 8 months, the dose was 7.5 mg, and for those over 8 months, the dose was 15 mg, added to 5% glucose solution 15~30ml, administered intravenously twice a day.
1.3 Determination of efficacy: markedly effective: treatment duration ≤ 3 days, temperature dropped to normal, cough significantly reduced, wheezing and shortness of breath disappeared, lung signs disappeared; effective: treatment time of ≤ 3 days, temperature drops, cough, wheezing, and shortness of breath alleviated, pulmonary signs significantly reduced or disappeared; ineffective: treatment time > 3 days, symptoms and signs did not improve.
2 Results: In the observation group, there were 12 markedly effective cases out of 38, 10 ineffective cases, with a total efficiency of 83.3%. In the control group, there were 5 markedly effective cases out of 24, 19 ineffective cases, with a total efficiency of 60.4%. The two groups were statistically treated, X2 = 4.74, P < 0.05, showing a significant difference.
3 Ambroxol is a new injectable type of expectorant drug that must metabolize cough products. Its mechanism of action on the respiratory system includes: ① thinning sputum, regulating the secretion of serous and mucinous substances, reducing the fluid viscosity of sputum, activating mucociliary function, promoting mucociliary transport, and facilitating sputum discharge, thus improving pulmonary ventilation and significantly improving clinical symptoms. While promoting the synthesis and secretion of pulmonary surfactant, it reduces surface tension and maintains the patency of the bronchial and alveolar lumen. ② Reducing the release of inflammatory mediators, inhibiting the release of acute inflammatory mediators from mast cells and white blood cells, and reducing the inflammatory response of lung tissue. ③ Exerting a stronger relaxing effect on tracheal and bronchial smooth muscle, especially histamine-induced smooth muscle spasm, maintaining airway patency. (4) Increasing antibiotic drug concentration in the airways, enhancing its ability to resist infection, and enhancing macrophage phagocytosis and bacterial killing ability.
Acute bronchiolitis is a more common lower respiratory tract infection in infants, especially in young infants aged 2 to 6 months. Its incidence is related to the anatomical characteristics of bronchitis at this age, making it easy for minor lumen obstruction due to sticky secretions, edema, and muscle contraction. We assisted in the conventional anti-infection, cough, and asthma treatments based on ambroxol in treating bronchiolitis. Observations showed that the speed of relieving clinical symptoms such as fever, cough, and wheezing was significantly superior to the conventional therapy control group, with a significant difference (P < 0.05).
It follows that ambroxol adjuvant treatment of bronchiolitis has a curative effect, significantly, with no significant side effects, and is worthy of clinical application.